Johnson & JohnsonJNJ
JNJ
About: Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Employees: 134,400
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
43% more first-time investments, than exits
New positions opened: 225 | Existing positions closed: 157
23% more call options, than puts
Call options by funds: $3.2B | Put options by funds: $2.61B
15% more funds holding in top 10
Funds holding in top 10: 163 [Q2] → 188 (+25) [Q3]
7% more capital invested
Capital invested by funds: $257B [Q2] → $275B (+$17.8B) [Q3]
2% more funds holding
Funds holding: 3,730 [Q2] → 3,798 (+68) [Q3]
2.41% less ownership
Funds ownership: 72.69% [Q2] → 70.29% (-2.41%) [Q3]
11% less repeat investments, than reductions
Existing positions increased: 1,516 | Existing positions reduced: 1,702
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$162
12%
upside
Avg. target
$179
24%
upside
High target
$215
49%
upside
8 analyst ratings
4 positive
50%
4 neutral
50%
0 negative
0%
Citigroup Joanne Wuensch 55% 1-year accuracy 26 / 47 met price target | 21%upside $175 | Buy Maintained | 11 Dec 2024 |
B of A Securities Tim Anderson 50% 1-year accuracy 3 / 6 met price target | 15%upside $166 | Neutral Reinstated | 10 Dec 2024 |
Wolfe Research Alexandria Hammond 33% 1-year accuracy 3 / 9 met price target | 32%upside $190 | Outperform Initiated | 15 Nov 2024 |
Guggenheim Vamil Divan 40% 1-year accuracy 8 / 20 met price target | 12%upside $162 | Neutral Maintained | 6 Nov 2024 |
Wells Fargo Larry Biegelsen 51% 1-year accuracy 24 / 47 met price target | 15%upside $166 | Equal-Weight Maintained | 16 Oct 2024 |
Financial journalist opinion
Based on 46 articles about JNJ published over the past 30 days
Positive
Seeking Alpha
2 days ago
Johnson & Johnson: Dividend Legend At A Discount
Johnson & Johnson's diversified revenue streams, significant presence in oncology and immunotherapy, and aggressive growth investments make it a strong defensive play. The company's low leverage, ample liquidity, and impressive free cash flow margin support its dividend sustainability and long-term growth. The stock is very attractively valued with an 18% potential upside.
Positive
24/7 Wall Street
2 days ago
Dow Losing Streak Longest in 50 Years: Grab These Bargain Blue-Chip Dividend Stocks Now
The Dow Jones industrial average is a price-weighted index of 30 blue-chip U.S.
Positive
Seeking Alpha
3 days ago
Of 63 Fortune500 Industry Leaders, 57 Pay Dividends, 38 Test 'Safer' & 1 Is Ideal To Buy
The June/July, 2024 Fortune Magazine revealed 500 biggest U.S. companies by-revenue and profits. Arnold-research focused on 66 December industry-leaders using YCharts 12/13/24 data for Profits from 63. Those 63 Fortune 500 industry leaders (F500IL) were segmented into 21 business sectors ranging (alphabetically) from aerospace/defense to wholesalers. By yield, MO topped-all F500IL. Top-ten Yields from PEP, PLD, SO, XOM, ADM, T, UPS, CVS, ET, & MO, averaged 4.71% in December.
Positive
Reuters
3 days ago
Health Rounds: J&J drug helps delay multiple myeloma in high-risk patients
The Johnson & Johnson drug Darzalex showed promise in helping keep a precancerous condition from progressing to the blood cancer multiple myeloma for those at high risk, according to results from a trial presented at the American Society of Hematology meeting in San Diego.
Positive
The Motley Fool
3 days ago
The Smartest Dividend Stocks to Buy With $500 Right Now
As an investor, your goal is to select quality stocks that will advance over a period of years -- but this doesn't mean you have to wait a long time for all of the rewards. If you add a few dividend stocks to your portfolio, you'll start collecting returns on a regular basis -- without lifting a finger.
Neutral
GlobeNewsWire
3 days ago
Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant
The European MCL Network Phase 3 TRIANGLE study, evaluated ibrutinib in combination with induction immunochemotherapy, both with and without an autologous stem cell transplant, followed by 24 months fixed-duration ibrutinib therapy1
Positive
Zacks Investment Research
4 days ago
FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC
The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer.
Neutral
Zacks Investment Research
5 days ago
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors
In the most recent trading session, Johnson & Johnson (JNJ) closed at $143.85, indicating a -1.89% shift from the previous trading day.
Positive
Reuters
5 days ago
US FDA declines to approve injection form of J&J's lung cancer drug
The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for a type of lung cancer, the drugmaker said on Monday.
Negative
Reuters
1 week ago
J&J accuses divisions of Cigna of helping drain its drug copay funds, WSJ reports
Johnson & Johnson has sued divisions of Cigna , accusing the health insurer of working with a drug-benefit middleman to drain J&J's financial-assistance funds earmarked for patients taking some of its pricier drugs, The Wall Street Journal reported on Friday.
Charts implemented using Lightweight Charts™